768 related articles for article (PubMed ID: 16609026)
21. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
22. Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography for detecting contralateral neck metastases in patients with head and neck squamous cell carcinoma.
Kim SY; Kim JS; Doo H; Lee H; Lee JH; Cho KJ; Choi SH; Nam SY; Roh JL
Oral Oncol; 2011 May; 47(5):376-80. PubMed ID: 21470899
[TBL] [Abstract][Full Text] [Related]
23. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
24. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
25. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
26. N2 disease in patients with head and neck squamous cell cancer treated with chemoradiotherapy: is there a role for posttreatment neck dissection?
Cho AH; Shah S; Ampil F; Bhartur S; Nathan CO
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1112-8. PubMed ID: 19917924
[TBL] [Abstract][Full Text] [Related]
27. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.
Malone JP; Gerberi MA; Vasireddy S; Hughes LF; Rao K; Shevlin B; Kuhn M; Collette D; Tennenhouse J; Robbins KT
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1119-25. PubMed ID: 19917925
[TBL] [Abstract][Full Text] [Related]
28. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic work-up and outcome of cervical metastases from an unknown primary.
Guntinas-Lichius O; Peter Klussmann J; Dinh S; Dinh M; Schmidt M; Semrau R; Mueller RP
Acta Otolaryngol; 2006 May; 126(5):536-44. PubMed ID: 16698706
[TBL] [Abstract][Full Text] [Related]
30. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
[TBL] [Abstract][Full Text] [Related]
31. Management of cervical lymph node recurrence of melanoma of the head and neck.
Fakhry N; Tessonnier L; Cohen F; Gras R; Grob JJ; Giovanni A; Mundler O; Zanaret M
Rev Laryngol Otol Rhinol (Bord); 2009; 130(4-5):211-4. PubMed ID: 20597399
[TBL] [Abstract][Full Text] [Related]
32. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
34. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT.
Bruschini P; Giorgetti A; Bruschini L; Nacci A; Volterrani D; Cosottini M; Ursino F; Mariani G; Fattori B
Acta Otorhinolaryngol Ital; 2003 Dec; 23(6):446-53. PubMed ID: 15198047
[TBL] [Abstract][Full Text] [Related]
36. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
37. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
38. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection.
Kim MJ; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2013 Mar; 20(3):899-905. PubMed ID: 23161114
[TBL] [Abstract][Full Text] [Related]
39. Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning.
Zalutsky MR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1958-60. PubMed ID: 16609003
[No Abstract] [Full Text] [Related]
40. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
